Iovance Biotherapeutics (NASDAQ: IOVA) aims to improve patient care for people living with cancer. Iovance is investigating T cell-based therapies, known as tumor infiltrating lymphocytes (TIL), which use a patient’s own immune cells to attack cancer.
Neuralink
89 followers
BridgeBio
14 followers
Beam
12 followers
Intellia Therapeutics
11 followers
Axsome Therapeutics
8 followers
BioAgilytix
3 followers
TG Therapeutics
3 followers
Element Biosciences
3 followers
Puma Biotechnology
3 followers
Personalis
6 followers
National Kidney Foundation
1 follower
Thermo Fisher Scientific
284 followers